These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 778998

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. The dopamine agonist piribedil with L-DOPA improves attentional dysfunction: relevance for Parkinson's disease.
    Turle-Lorenzo N, Maurin B, Puma C, Chezaubernard C, Morain P, Baunez C, Nieoullon A, Amalric M.
    J Pharmacol Exp Ther; 2006 Nov; 319(2):914-23. PubMed ID: 16920993
    [Abstract] [Full Text] [Related]

  • 25. [Polygraphic recording of tremor and of hypertonic phenomena. Application to the action of various drugs].
    Truelle JL, Chanelet J, Bastard J, Emile J.
    Rev Neurol (Paris); 1975 Jan; 131(1):29-42. PubMed ID: 1101346
    [Abstract] [Full Text] [Related]

  • 26. [D,L-threo-3,4-dihydroxyphenylserine (D,L-threo-DOPS) treatment on the patients with Parkinson's disease or pure akinesia].
    Kondo T.
    Rinsho Shinkeigaku; 1984 Mar; 24(3):280-8. PubMed ID: 6432393
    [No Abstract] [Full Text] [Related]

  • 27. [Treatment of Parkinsonic syndrome with levo-Dopa. Case reports].
    Rosati G, Agnetti V, Mura F, Granieri E.
    Minerva Med; 1974 May 02; 65(33):1811-23. PubMed ID: 4602058
    [No Abstract] [Full Text] [Related]

  • 28. Clinical and pharmacological evaluation of the effects of piribedil in patients with parkinsonism.
    McLellan DL, Chalmers RJ, Johnson RH.
    Acta Neurol Scand; 1975 Jan 02; 51(1):74-82. PubMed ID: 1091122
    [Abstract] [Full Text] [Related]

  • 29. [Experimental and clinical study on the dopaminergic receptor stimulating agents (author's transl)].
    Ohmoto T, Miyamoto T, Baba Y.
    No To Shinkei; 1977 Jul 02; 29(7):?31-40. PubMed ID: 409419
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. End-of-dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients: a pharmacokinetic/pharmacodynamic, randomized, double-blind study.
    Simon N, Micallef J, Reynier JC, Lesourd M, Witjas T, Alicherif A, Azulay JP, Blin O.
    Mov Disord; 2005 Jul 02; 20(7):803-9. PubMed ID: 15726579
    [Abstract] [Full Text] [Related]

  • 34. Impaired activity of the supplementary motor area in akinetic patients with Parkinson's disease. Improvement by the dopamine agonist apomorphine.
    Rascol OJ, Sabatini U, Chollet F, Montastruc JL, Marc-Vergnes JP, Rascol A.
    Adv Neurol; 1993 Jul 02; 60():419-21. PubMed ID: 8420165
    [No Abstract] [Full Text] [Related]

  • 35. [Attempted direct etiological treatment of Huntington's chorea. Case reports].
    Majeron MA, Ambrosoli C, Armocida G, Finavera L, Quisi Q.
    Minerva Med; 1980 Apr 21; 71(16):1213-20. PubMed ID: 6445524
    [Abstract] [Full Text] [Related]

  • 36. Caffeine and the antiparkinsonian response to levodopa or piribedil.
    Shoulson I, Chase T.
    Neurology; 1975 Aug 21; 25(8):722-4. PubMed ID: 125389
    [Abstract] [Full Text] [Related]

  • 37. Bromocriptine: long-term low-dose therapy in Parkinson's disease.
    Teychenne PF, Bergsrud D, Elton RL, Racy A.
    Clin Neuropharmacol; 1986 Aug 21; 9(2):138-45. PubMed ID: 3708599
    [Abstract] [Full Text] [Related]

  • 38. The role of a dihydromorphanthridine derivative in Parkinson's patients treated with L-dopa. A preliminary report.
    Wycis HT.
    Confin Neurol; 1972 Aug 21; 34(2):130-5. PubMed ID: 4666056
    [No Abstract] [Full Text] [Related]

  • 39. Apomorphine and piribedil in rats: biochemical and pharmacologic studies.
    Butterworth RF, Poignant JC, Barbeau A.
    Adv Neurol; 1975 Aug 21; 9():307-26. PubMed ID: 1170716
    [Abstract] [Full Text] [Related]

  • 40. Individual manifestations of Parkinson's disease after ten or more years of levodopa.
    Klawans HL.
    Mov Disord; 1986 Aug 21; 1(3):187-92. PubMed ID: 3504244
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.